JP2019523265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523265A5 JP2019523265A5 JP2019503925A JP2019503925A JP2019523265A5 JP 2019523265 A5 JP2019523265 A5 JP 2019523265A5 JP 2019503925 A JP2019503925 A JP 2019503925A JP 2019503925 A JP2019503925 A JP 2019503925A JP 2019523265 A5 JP2019523265 A5 JP 2019523265A5
- Authority
- JP
- Japan
- Prior art keywords
- pulmonary fibrosis
- risk
- subject
- pharmaceutical composition
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 32
- -1 racemates Chemical class 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000001475 halogen functional group Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 3
- 206010039163 Right ventricular failure Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 239000010425 asbestos Substances 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 201000004193 respiratory failure Diseases 0.000 claims description 3
- 229910052895 riebeckite Inorganic materials 0.000 claims description 3
- 239000000779 smoke Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016902978 | 2016-07-28 | ||
| AU2016902978A AU2016902978A0 (en) | 2016-07-28 | Compositions for the treatment of pulmonary fibrosis | |
| PCT/AU2017/050784 WO2018018091A1 (en) | 2016-07-28 | 2017-07-28 | Compositions for the treatment of pulmonary fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523265A JP2019523265A (ja) | 2019-08-22 |
| JP2019523265A5 true JP2019523265A5 (cg-RX-API-DMAC7.html) | 2021-10-21 |
| JP6983222B2 JP6983222B2 (ja) | 2021-12-17 |
Family
ID=61015577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503925A Active JP6983222B2 (ja) | 2016-07-28 | 2017-07-28 | 肺線維症の処置のための組成物 |
Country Status (21)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ736165A (en) * | 2015-03-18 | 2022-07-01 | Vectus Biosystems Ltd | Compositions for the treatment of kidney and/or liver disease |
| BR112019001510B1 (pt) * | 2016-07-28 | 2022-11-08 | Vectus Biosystems Limited | Composto, e, uso de um composto para manufatura de um medicamento para tratar profilática ou terapeuticamente fibrose pulmonar, ou uma enfermidade relacionada em um indivíduo com fibrose pulmonar ou em risco de desenvolver fibrose pulmonar |
| ES3067250A1 (es) * | 2024-11-08 | 2026-05-20 | Univ Valencia | Tratamiento del Síndrome de Dificultad Respiratoria Aguda (SDRA) con inhibidores de GPBP1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX368865B (es) * | 2013-09-17 | 2019-08-02 | Vectus Biosystems Ltd | Composiciones para el tratamiento de hipertension y/o fibrosis. |
| US9630935B2 (en) | 2013-09-17 | 2017-04-25 | Vectus Biosystems Limited | Compositions for the treatment of hypertension and/or fibrosis |
| JP6454348B2 (ja) * | 2013-12-19 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 窒素複素環誘導体およびその医薬品への応用 |
| WO2016046782A1 (en) * | 2014-09-26 | 2016-03-31 | Glenmark Pharmaceuticals S.A. | Imidazole biaryl compounds as s-nitrosoglutathione reductase inhibitors |
| WO2016107906A1 (en) * | 2014-12-31 | 2016-07-07 | Fibrostatin, S.L. | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition |
| SG11201707561RA (en) * | 2015-03-18 | 2017-10-30 | Vectus Biosystems Ltd | Compositions for the treatment of fibrosis and fibrosis-related conditions |
| NZ736165A (en) * | 2015-03-18 | 2022-07-01 | Vectus Biosystems Ltd | Compositions for the treatment of kidney and/or liver disease |
| EP3353147B1 (en) * | 2015-09-22 | 2021-01-13 | Vectus Biosystems Limited | Synthesis of terphenyl compounds |
| BR112019001510B1 (pt) * | 2016-07-28 | 2022-11-08 | Vectus Biosystems Limited | Composto, e, uso de um composto para manufatura de um medicamento para tratar profilática ou terapeuticamente fibrose pulmonar, ou uma enfermidade relacionada em um indivíduo com fibrose pulmonar ou em risco de desenvolver fibrose pulmonar |
-
2017
- 2017-07-28 BR BR112019001510-8A patent/BR112019001510B1/pt active IP Right Grant
- 2017-07-28 CN CN201780046913.9A patent/CN109661387B/zh active Active
- 2017-07-28 RU RU2019104161A patent/RU2747801C2/ru active
- 2017-07-28 AU AU2017301113A patent/AU2017301113B2/en active Active
- 2017-07-28 US US16/319,957 patent/US10919863B2/en active Active
- 2017-07-28 WO PCT/AU2017/050784 patent/WO2018018091A1/en not_active Ceased
- 2017-07-28 UA UAA201901421A patent/UA124468C2/uk unknown
- 2017-07-28 MX MX2019001183A patent/MX393490B/es unknown
- 2017-07-28 NZ NZ750495A patent/NZ750495A/en unknown
- 2017-07-28 MY MYPI2019000419A patent/MY192402A/en unknown
- 2017-07-28 CA CA3030309A patent/CA3030309C/en active Active
- 2017-07-28 FI FIEP17833106.2T patent/FI3490970T3/fi active
- 2017-07-28 JP JP2019503925A patent/JP6983222B2/ja active Active
- 2017-07-28 ES ES17833106T patent/ES2965041T3/es active Active
- 2017-07-28 KR KR1020197005978A patent/KR102377981B1/ko active Active
- 2017-07-28 SG SG11201900182PA patent/SG11201900182PA/en unknown
- 2017-07-28 EP EP17833106.2A patent/EP3490970B1/en active Active
- 2017-07-28 IL IL264392A patent/IL264392B2/en unknown
- 2017-07-28 DK DK17833106.2T patent/DK3490970T3/da active
-
2019
- 2019-01-25 PH PH12019500180A patent/PH12019500180A1/en unknown
- 2019-02-20 ZA ZA2019/01099A patent/ZA201901099B/en unknown
-
2021
- 2021-01-06 US US17/142,586 patent/US11401245B2/en active Active